In the US, where it is quickly spreading, a new Covid sub-variant is raising some alarm.
What do you need to know about XBB.1.5 given that some cases have also been reported in the UK?
It is another another offspring of the Omicron Covid variety, which is widely prevalent. Since surfacing in late 2021, Omicron has outperformed the preceding Alpha, Beta, Gamma, and Delta coronavirus strains.
There are numerous other infectious sub-variants of Omicron.
It is believed that the symptoms of XBB.1.5 are comparable to those of earlier Omicron strains. Most people have symptoms similar to a cold.
Is XBB.1.5 a more contagious or harmful strain
From XBB, which started to circulate in the UK in September 2022, came XBB.1.5.
The same mutation that allowed XBB to overcome the body’s defensive defenses also made it less able to infect human cells.
A mutation called F486P in XBB.1.5, according to Prof. Wendy Barclay of Imperial College London, restores this capacity to connect to cells while maintaining immunity. It spreads more readily as a result.
She claimed that these evolutionary alterations served as “stepping stones” for the virus as it continued to develop new ways to get through the body’s defenses.
As part of ongoing efforts to track variations, the Wellcome Sanger Institute in Cambridge is currently sequencing at least 5,000 Covid samples per week.
Dr. Ewan Harrison of the institute believes that XBB.1.5 most likely developed when a person contracted two distinct Omicron types:
“A piece of the genome from one virus joins forces with a piece of the genome from another virus, and they combine, and that continues to spread.”
In comparison to other sub-variants thus far observed, XBB.1.5 has a “growth advantage,” according to the World Health Organization (WHO).
However, the WHO claimed that there was currently no evidence to suggest that it was more dangerous or serious than earlier Omicron forms.
Where is the propagation of XBB.1.5
XBB.1.5 is the predominant strain and is expected to be responsible for more than 40% of Covid cases in the United States.
It has quickly surpassed previous Omicron variants, accounting for only 4% of cases at the beginning of December.
Recently, there have been more Covid hospital admissions across the US, and the government has reinstituted its free testing program.
US reinstates no-cost Covid tests at hom
Could the UK market for the XBB.1.5 variation grow?
It seems plausible. Five Omicron waves hit the UK in 2022, and it seems certain that there will be more peaks in instances.
One in 25 Covid cases in the UK had XBB.1.5, according to Wellcome Sanger data for the week ending on Saturday, December 17.
However, that was based on only nine samples, so we must wait to obtain a more accurate picture.
Next week, a report on variations spreading in the UK is expected to be released by the UK Health Security Agency.
If the mutation becomes more prevalent in the UK, as Prof. Barclay predicted, there would be an increase in hospitalizations.
According to NHS England, the flu and Covid “twindemic” concerns have already come true, placing further strain on an already overburdened NHS.
This winter, who is eligible for a Covid booster? How to care for oneself in the event of COVID
Most people have good protection against major illness thanks to COVID vaccinations.
Do researchers worry about XBB.1.5?
Prof. Barclay stated that there was “no indication” that XBB.1.5 would “break through” the defense against serious sickness offered by immunizations, hence she was not overly concerned about the general UK population.
She is concerned, however, about the potential impact on the weak, notably the immunocompromised, who benefit less from Covid vaccinations.
The London School of Hygiene and Tropical Medicine’s Prof. David Heymann admitted that there was still a lot to learn about this most recent variety.
However, he claimed that in nations with high vaccination rates and a history of diseases, like the UK, it was unlikely to result in significant issues.
His concern was for nations like China, where long-term lockdowns resulted in low vaccination rates as well as low levels of natural immunity.
Prof. Heymann stated that in order to observe how the variation acts in a non-immune population, China must exchange clinical data on affected individuals.